

Biomarkers and prognostic stratification in psoriatic arthritis

L. Bogliolo, G. Crepaldi, R. Caporali

U.O.C. Reumatologia, IRCCS Fondazione Policlinico S. Matteo, Pavia, Università di Pavia

SUMMARY

In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.

Key words: psoriatic arthritis, biomarkers, joint damage

Reumatismo, 2012; 64 (2): 88-98

INTRODUCTION

The term biomarker comes from “biological markers”, that the US National Institutes of Health (NIH) Biomarkers and Surrogate Endpoint Working Group defines “as objective parameters that can be measured and evaluated as an indicator of biological processes, pathogenic processes or pharmacological responses to therapeutic intervention” (1).

In the pathogenic processes, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and outcome of the disease. In the last ten years, with the new and now consolidated concepts of “early diagnosis” (2-5) and “treat to target” (6, 7) a huge effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response in rheumatoid arthritis (RA) (8, 9).

For this, a great endeavour has been made for the identification of serological, clinical and instrumental parameters, helpful

for identify patients at risk of developing persistent and aggressive disease, requiring early and aggressive therapeutic intervention. Among these parameters, acute phase reactants(10), rheumatoid factor (RF) and its isotypes, anti-citrullinated peptide antibodies (ACPA) (11-18), simple clinical index as the number of swollen joints and composite index as the disease activity score (DAS) (19), the presence of ultrasonographic power doppler despite clinical remission of the disease, the bone oedema on MR imaging and the erosions in MR and plain radiographs (20-26), have been identify in RA as biomarkers of disease activity or prognostic factors and currently used in the evaluation of RA patients.

Unfortunately, in Psoriatic Arthritis (PsA), traditional methods in evaluation of disease assessment and research for biological markers, have not kept pace with the accelerated development of the concept of early diagnosis and prognostic stratification, the appearance of the new

Corresponding author:
Roberto Caporali
U.O.C. Reumatologia
IRCCS Fondazione S. Matteo
Piazzale Golgi, 2 - 27100 Pavia
E-mail: caporali@smatteo.pv.it

therapeutic options and also with the new PsA classification and the re-evaluation of their different clinical subsets (27) (from the Moll and Wright to the CASPAR classification) (28-30).

So, in PsA, serological biomarkers, such as the domains assessing clinical outcome (for example swollen and tender joints, visual analogical scale (VAS) for patient and physician global assessment, VAS for pain, Health Assessment Questionnaire (HAQ)), have been frequently borrowed from RA because of the similarities between the diseases and the good response to the same therapeutic approach with biological drugs (31, 32). Nevertheless, this “copy-past” approach from RA to PsA have sometimes lead to inappropriate choices of biomarkers and subsequently to incorrect conclusions. Compared with RA, PsA is a more complex disease from both clinical and pathogenetic point of view and the use of RA biomarkers may be reductive and make diagnosis and prognosis difficult.

Recently, the increased data demonstrating the different pathogenesis and disease process in PsA (33) and RA (34), rises new attention among PsA researchers in the identification and validation of specific biomarkers. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarker development in psoriasis and PsA:

1. articular disease diagnosis in patients with psoriasis;
2. joint damage in PsA (35).

With particular attention on the second key area, in the 2008 GRAPPA meeting held in Leeds (UK), a special working group for the development of soluble and synovial tissue biomarkers in PsA, under the umbrella of the Outcome Measures in Rheumatology (OMERACT), began to develop validation tools reflecting the variety of different process and phisiopathological mechanisms in PsA (37).

The aim of this review is to summarize the actually available biomarkers for PsA with a particular attention on those that may help clinicians in the prognostic stratification of PsA patients.

■ SERUM BIOMARKERS

Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)

Recently, Chandran and co-workers show that highly sensitive CRP (hs-CRP) levels are higher in PsA patients compared with those observed in patients with psoriasis alone and that it may be a biomarker of PsA because indicates additional inflammation (36). Nevertheless, hs-CRP is not available for routine analysis and classical acute phase reactant, such as ESR and CRP, are generally used. However, ESR and CRP are reported as normal in up to 50% of patients with PsA despite clinically active disease; their contribute for diagnosis is very limited while they may have a role in the assessment of disease activity (37, 38). More than 20 years ago, Gladmann and co-workers found that acute phase reactants correlate with a higher number of involved joints and represent a negative prognostic predictor, especially in the peripheral subset of PsA with respect to the axial and enthesitic form (38). In a recent study, CRP has been evaluated as a marker for response to therapeutic intervention with tumor necrosis factor-alpha (TNFalfa) antagonists in patients with PsA. Moreover, higher levels of CRP were found to be a good predictor of response and along with other clinical features (lower HAQ-DI score, polyarthritis) increased the chance of achieving clinical improvements with anti-TNFalfa drugs (39).

Cytokines

Significantly higher serum levels of IL-6, IL-10, soluble receptor of IL-2 (sIL-2R) and IL-1 receptor antagonists (IL-1ra) were found in patients with PsA in comparison with healthy volunteers (40). In previous studies, a correlation between IL-6 levels and the number of painful and swollen joints was demonstrated (41); moreover, serum IL-6 appears to be a better marker of inflammation than the classical acute phase reactants (ESR and CRP) and correlates with the number of affected joints (42) in patients with psoriasis and inflammatory joint disease. More recently, Elkayam O et

al. did not find any correlation between IL6 levels and severity of joint involvement. This discrepancy may be due to differences in the patients' population (polyarticular vs oligoarticular involvement) suggesting that this association may exist only in polyarticular arthritis (42). However, studies of markers of inflammation both in healthy subjects and in patients with RA have shown a statistically significant circadian variation in levels of IL-6, suggesting that it would be a less robust marker than those without diurnal variation (43).

In the same study by Elkayam and co-workers, no association was found between levels of IL-10 and sIL-2R and clinical parameters, whereas levels of IL-1ra seem to correlate with the number of tender and swollen joints in patients with peripheral form. No significant association was found between IL-1ra serum levels and clinical lumbar involvement, suggesting that IL-1ra, as well as IL-6, may be useful in the future as serum biomarkers of disease activity in PsA, especially in the peripheral form (42).

Autoantibodies

Rheumatoid factor (RF) is the longest-standing autoantibody test to distinguish RA from other forms of arthritis and included in the recently published 2010 classification criteria for RA (4), replacing the 1987 American College of Rheumatology (ACR) criteria (44). It has been documented as a useful marker for the diagnosis and the prognosis of RA, with a sensitivity of 68-81% and a specificity of 60-85%, until the identification of anti cyclic citrullinated peptides antibodies (ACPA), showing a higher specificity (90-98%) and comparable sensitivity (45). Although RF facilitated the classification of polyarthritis, the differential diagnosis between RA and PsA is a complex clinical work and the utility of autoantibodies is frequently considered marginal. For example, it is well known that in adult people of Northern Italy, RF may be related to HCV infection, which occurs in 5 to 10% of the general population, not associated with arthritis (46). This may lead to an in-

creased rate of RF positivity in otherwise seronegative arthritis (47).

Despite in the Moll and Wright classification criteria for PsA (30) RF is an exclusion criteria and in the new CASPAR classification a negative RF is considered as a minor criteria for the diagnosis (31), RF was found in a variable percentage of PsA, ranging between 2% and 16,5% in patients with psoriasis and inflammatory arthritis (48-51). In all of the studies no significant correlation was found between RF positivity and erosive disease or number of swollen and/or involved joints.

More than RF, ACPA are considered highly specific markers of RA, with a predictive value for subsequent structural damage (52, 53), persistence of synovitis (54, 55), the need for intensive treatment (56), decline of function in the course of disease (57) and premature death (58). In undifferentiated Polyarthritis (UPA), several studies describe high predictive value of ACPA positivity at baseline with respect to the development of overt RA at 1-year follow-up (54, 55, 59, 60). Moreover, the presence of ACPA has been linked to development of RA even in healthy populations (61).

Despite their high specificity for RA, ACPA have also reported in other conditions such systemic lupus erythematosus (SLE) (62, 63), Sjögren syndrome (64), systemic sclerosis (65) and others connective tissue disease (66) and in the majority of cases ACPA were associated with erosive joint involvement (64, 65, 67, 68) suggesting that the risk of deforming and erosive arthritis is closely related to ACPA positivity. Moreover, ACPA have been observed also in psoriatic arthritis, with a proportion ranging from 5 to 16% (51, 53, 67, 68). In PsA, as in RA, ACPA seems to be useful in detecting those patients with a higher number of involved and swollen joints (51, 59) and with an increased risk of erosion, requiring early DMARD treatment with conventional drugs or biological agents (53).

It is possible that RA with RF or ACPA positivity may occur in patients with psoriasis, even if the reported association between ACPA and erosive arthritis in more

then one disease, different from RA, require a more complex explanation. Interesting, in the study by our group, enthesitis, dactylitis and axial or DIP involvement was similar in the ACPA positive patients compared to the ACPA negative group, meaning that ACPA are not restricted to those patients with a clear-cut clinical picture of RA, as they may be present in patients with features usually regarded as typical of PsA and seronegative spondyloarthropathies.

Circulating mediators of cartilage and bone remodelling

Cartilage destruction and remodeling are features of inflammatory arthritis. The products of cartilage synthesis and destruction are released into the serum during this process and may also serve as biomarkers (38). Whereas RA primarily results in bone and cartilage resorption, PsA combines destructive elements with anabolic bone responses and cartilage apposition (70).

Osteoprotegerin (OPG) is a cytokine and a potential marker of periostitis and new bone formation which is a characteristic feature of PsA that differentiated it from other inflammatory arthritis. Recent studies have shown that an increased level of OPG may be used as a marker of PsA in patients with psoriasis and may indicate the presence of new bone formation (38).

Another informative marker of cartilage remodeling is the ratio between C-propeptide of type II collagen (CPII) and collagen fragment neopeptides (C2C), that reflects the balance between type II collagen synthesis and degradation. This parameter is an independent biomarker for PsA and may indicate new bone formation. Also, matrix metalloproteinase-3 (MMP-3), an enzyme with a role in the destruction of cartilage and bone in rheumatic diseases characterized by synovitis, has been shown to be associated with PsA (38). However, these biomarkers may be useful to identify patients with psoriasis at increased risk of having PsA, helping in early diagnosis, but no association was found with disease activity and prognosis of PsA.

Instead, the extent of bone loss at the pe-

ripheral joints is associated with elevated circulating macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) concentrations in serum samples from PsA patients. Serum levels of M-CSF in particular are elevated in patients with erosive arthritis and strongly correlate with severity of peripheral erosive disease. Therefore, markers such as M-CSF and RANKL may have a role to identify patients in whom progressive or accelerated joint damage will develop (71).

Furthermore, cartilage oligomeric matrix protein (COMP), a glycoprotein expressed in cartilage, tendons, meniscus and synovial membrane, can be used as a parameter for the extent of cartilage destruction because its release pattern in serum may reflect cartilage turnover. Serum levels of COMP have been demonstrated to be an indicator for disease activity in patients with PsA, because those with active disease showed significantly elevated COMP serum levels compared to the patients with low disease activity. Indeed, this parameter correlates significantly with acute-phase reactants (CRP) and the number of swollen joints (72).

Clinical biomarkers

PsA is classified as a spondyloarthropathy because of the presence of axial involvement in up to 40% of patients with a characteristic asymmetrical distribution (73, 74). Nevertheless, prognostic factors have not been extensively studied for the axial form of PsA and it is not clear from the literature if axial involvement imply a worse prognosis of PsA patients (75, 76). Moreover, it is frequently difficult to establish with certainty the presence of inflammatory back pain (IBP) in patients with PsA (77) who generally have less pain than patients with ankylosing spondylitis (AS) (78).

The only demonstrated clinical predictor of aggressive PsA is the involvement of the peripheral joints. Cohort studies have suggested a link between inflammation and joint damage, showing that swollen joints are a predictor of future increase in the clinically damaged joint count (79, 80)

and of radiologic progression (53, 81). Particularly, in the study of Gladmann DD et al., polyarticular onset of the disease, with more than five involved joints and a high medication level at presentation to the clinic, predicted the progression of the disease, with an increased joint damage (40). In another study, the polyarticular disease at onset predicted not only the development of clinical deformities but also an erosive disease (82). More recently, Simon P et al concluded that also an increasing number of swollen joints, during a 12-month period of follow-up, heralds progression of radiological damage in PsA patients (83).

■ IMAGING

Imaging studies have demonstrated the direct link between inflammation and joint damage in RA, using a combination of ultrasound (US), conventional radiography and MRI (72, 84, 85). In PsA, such data are currently unavailable and the link between inflammation of entheses and/or synovium with joint damage, is still under investigation. Nevertheless, similar to RA (86), in observational cohort studies in PsA radiological damage was found to be predictive of increased mortality (87).

Recently, US and MRI have been validated as sensitive techniques in the early diagnosis of synovitis (88) and enthesitis (89) in PsA, but no clear data are available on their prognostic value.

Although the interest in this field is growing, US and MRI studies of PsA are fewer than those in RA and further studies are needed to clarify the relevance of the typical aspects of extracapsular enhancement and enthesitis of PsA. At now, these characteristics seems to be more relevant to underline the “entheses-related origin” of PsA proposed in contrast to the primarily synovial inflammation of RA (90, 91), than useful to identify prognostic aspect of the disease.

Moreover, bone erosions in PsA are probably less frequent and progressive than in RA and bone oedema is unlikely to predict the appearance of erosions in patients

with PsA (92). So, while many GRAPPA members expressed considerable support for the advantages provided by MRI as an outcome measure in PsA, since no scoring technique has yet been validated, the inclusion of MRI as a primary outcome imaging tool may be premature. Thus, plain radiographs of hands and feet were considered an essential primary radiologic outcome measure for progression of erosions, with MRI sub-study strongly recommended, where feasible.

An early use of MRI has recently described also for diagnostic and prognostic stratification of patients with axial involvement in which the clinical symptoms of low-back pain and the typical radiographic aspects may be observed only when the disease is still consolidated (79).

■ OTHERS BIOMARKERS: NEW PROSPECTIVE FROM THE GENETIC TO CELLULAR AND HISTOLOGICAL BIOMARKERS

Genetic factors are very important not only for psoriasis susceptibility (93, 94), but also in the expression of PsA, and their role is evident when considering the strong heritability of PsA (95). Nevertheless, genetic association studies of PsA are limited by its changing articular pattern over time and because of each pattern of PsA may not be genetically distinct, considering the frequent overlapping between clinical subgroups. So, although the strong evidence for the genetic basis of PsA (96) only a few genes have been identified thus far as independent susceptibility genes for PsA.

At the moment genetic factors appear to be related with the clinical phenotype of PsA (axial involvement, polyarticular involvement) rather than with diagnosis or prognosis (97-99).

The HLA-DR4 antigen has been reported to be increased in PsA with a clinical picture resembling RA and particularly in patients who developed radiological erosions (100, 101), but recently, Queiro-Silva et al. do not support the notion of the HLA-

DR4 antigen as a marker of disease severity (102).

A positive correlation with disease activity was found for peripheral blood mononuclear cell (PBMC) gene expression of bone morphogenetic protein-4 (BMP-4), emphasizing the importance of alterations in bone metabolism in active PsA and identifying BMP-4 as a disease severity marker. Another marker that may be relevant in the near future is represented by the increased number of circulating osteoclast precursors (OCPs) in blood samples from PsA patients that may indicate the presence of a severe erosive disease (104, 105).

Finally, some typical aspects of synovial biology of PsA, such as synovial infiltrate, expression of pro-inflammatory cytokines and adhesion molecules and dysregulated angiogenesis with increased vascularity, have been recently investigated as possible prognostic marker (106-110). Nevertheless, although much has been learned about the pathogenesis of PsA, much remains to be defined regarding the link between synovial biology and different disease outcomes. The rapid advance in ultrasound technology, through minimal invasive biopsy, has enabled the collection of synovial tissue from arthritis patients (111) with a realistic prospect to correlate different PsA phenotypes, ultrasound images and cellular and molecular mechanisms of abnormal bone remodeling of PsA, useful to improve prognostic algorithms.

■ CONCLUSIONS

In recent years, there has been a growing appreciation of the potential severity of PsA. Whereas PsA was previously considered to be a relatively mild form of arthritis, it is now clear that it can be progressive, destructive and deforming (82, 112-114). In fact, about 20% of the patients develop a very destructive disabling form of arthritis and a recent study of early onset PsA showed that within two years of onset, 47% of patients demonstrated at least one bone erosion (115). Disability and quality of life are adversely affected in patients with PsA

to an equivalent degree as in RA (122); so, remission is considered to be the ultimate goal of therapy in PsA like in RA (9, 33). Nevertheless, between the rheumatic diseases, experts recognized that remission in PsA may be difficult to achieve and maintain and it has been concluded that “near remission” or “low disease activity” could be an appropriate goal, today acceptable for PsA (116, 117).

So, it seems crucial from a practical point of view, to identify prognostic factors in PsA that enable clinicians to differentiate from the beginning the more aggressive form of disease and to treat it accordingly. At the moment, it is quite clear that polyarticular onset, with more than 5 joints involved, high ESR at presentation, ACPA positivity and the presence of erosion at plan radiographs, identify an erosive and progressive arthritis, in which aggressive and early therapy may improve the prognosis (3, 5, 7-9).

The recent update on biomarkers in PsA from the GRAPPA 2010 annual meeting, summarize the current knowledge biomarkers but in the same time underline that one important critical area is the identification of biomarkers of joint damage in PsA, including both erosive change and new bone formation. More studies on this important topic are warranted in the next future.

■ REFERENCES

1. Biomarkers Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* 2001; 69: 89-95.
2. Quinn MA, Emery P. Are early arthritis clinics necessary? *Best Pract Res Clin Rheumatol* 2005; 19 (1): 1-17.
3. Breedveld F. The value of early intervention in RA: a window of opportunity. *Clin Rheumatol* 2011; 30 (Suppl 1): s33-9.
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. 2010 Rheumatoid arthritis classification criteria. *Arthritis Rheum* 2010; 62: 2569-81.
5. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. *Curr Opin Rheumatol* 2009; 21: 118-23.

6. Schoels M, Knevel R, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas DT, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. *Ann Rheum Dis* 2010; 69: 638-43.
7. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Brumester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010; 69 (4): 631-7.
8. Schoels M, Bombardier C, Aletaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. *J Rheumatol* 2011; 39: 20-5.
9. Kelling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, et al. Testing of the preliminary OMERACT validation criteria for biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. *J Rheumatol* 2007; 34: 623-33.
10. Rhodes B, Fürnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. *Nat Rev Rheumatol* 2011; 7: 282-9.
11. Bobbio-Pallavicini F, Caporali R, Alpini C, Moratti R, Montecucco C. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. *Ann NY Acad Sci* 2007; 1109: 287-95.
12. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis factor alpha inhibitors in rheumatoid arthritis. *Ann Rheum Dis* 2007; 66: 302-7.
13. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. *Arthritis Res Ther* 2010; 12: 203.
14. Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). *Ann Rheum Dis* 2004; 63: 1090-5.
15. Vencovský J, Macháček S, Sedová L, Kafková J, Gatterová J, Pesáková V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. *Ann Rheum Dis* 2003; 62: 427-30.
16. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. *J Rheumatol* 2005; 32: 231-8.
17. Johnson PM, Faulk WP. Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis. *Clin Immunol Immunopathol* 1976; 6: 414-30.
18. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. *Ann Rheum Dis* 2006; 65: 453-8.
19. Dougados M, Aletaha D, van Riel P. Disease activity measures for rheumatoid arthritis. *Clin Exp Rheumatol* 2007; 25 (5 Suppl 46): S22-9.
20. Scirè CA, Montecucco C, Codullo V, Epis O, Todoerti M, Caporali R. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power doppler signal predicts short-term relapse. *Rheumatology (Oxford)* 2009; 48: 1092-7.
21. Wells AF, Haddad RH. Emerging role of ultrasonography in rheumatoid arthritis: optimizing diagnosis, measuring disease activity and identifying prognostic factors. *Ultrasound Med Biol* 2011; 37: 1173-84.
22. Suter LG, Fraenkel L, Braithwaite RS. Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis. *Arthritis Care Res* 2011; 63: 675-88.
23. Cimmino MA, Barbieri F, Zampogna G, Camellino D, Paparo F, Parodi M. Imaging in arthritis: quantifying effects of therapeutic intervention using MRI and molecular imaging. *Swiss Med Wkly* 2012; 141: w13326.
24. Boesen M, Ostergaard M, Cimmino MA, Kubassova O, Jensen KE, Bliddal H. MRI quantification of rheumatoid arthritis: current knowledge and future perspectives. *Eur J Radiol* 2009; 71: 189-96.
25. Wakefield RJ, Gibbon WW, Conaghan PG, O'Connor P, McGonagle D, Pease C, et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. *Arthritis Rheum* 2000; 43: 2762-70.
26. Palosaari K, Vuotila J, Takalo R, Jartti A, Niemelä RK, Karjalainen A, et al. Bone oedema predicts erosive progression on wrist MRI in early RA - a 2 yr observational MRI and NC scintigraphy study. *Rheumatology* 2006; 45: 1542-8.
27. Helliwell P, Marchesoni A, Peters M, Barker M, Wright VA. Re-evaluation of the osteoarticular manifestation of psoriasis. *Br J Rheumatol* 1991; 30: 339-45.
28. Moll JM, Wright V. Psoriatic arthritis. *Semin Arthritis Rheum* 1973; 3: 55-78.
29. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum*. 2006; 54: 2665-73.
30. Tillett W, Costa L, Jadon D, Wallis D, Cavill

- C, McHugh J, et al. The CLASSification for Psoriatic ARthritis (CASPAR) Criteria - A Retrospective Feasibility, Sensitivity, and Specificity Study. *J Rheumatol.* 2012; 39: 154-6.
31. Saber TP, Ng CT, Renard G, Lynch BM, Pontifex E, Walsh CAE, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? *Arthritis Res Ther* 2010;12:R94.
 32. Chimienti MS, Graceffa D, Perricone R. Anti-TNF α discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? *Autoimmun Rev* 2011; 10: 636-40.
 33. Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. *Semin Arthritis Rheum* 2008; 38: 83-100.
 34. McInnes IB, O'Dell JR. State of the art: rheumatoid arthritis. *Ann Rheum Dis* 2010; 69: 1898-906.
 35. Ritchlin CP, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease JP, et al. Biomarkers in Psoriasis and Psoriatic arthritis: GRAPPA 2008. *J Rheumatol* 2010; 37: 462-7.
 36. Chandran V, Cook RJ, Edwin J, Shen H, Pellet FJ, Shanmugarajah S, et al. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. *Rheumatology* 2010; 49: 1399-405.
 37. Punzi L, Podswiadek M, Oliviero F, Lonigro A, Modesti V, Ramonda R, et al. Laboratory findings in psoriatic arthritis. *Reumatismo* 2007; 59 (Suppl 1): 52-5.
 38. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate risk model. *J Rheumatol* 1995; 22: 675-9.
 39. Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. *Ann Rheum Dis* 2010; 69: 394-9.
 40. Elkayam O, Yaron I, Shirazi I, Yaron M, Caspi D. Serum levels of IL-10, IL-6, IL-1ra and sIL-2R in patients with psoriatic arthritis. *Rheumatol Int* 2000; 19: 101-5.
 41. Spadaro A, Taccari E, Riccieri V, Sensi F, Silli Scavelli A, Zoppini A. Interleukin 6 and soluble interleukin-receptor in psoriatic arthritis: correlation with clinical and laboratory parameters. *Clin Exp Rheumatol* 1996; 4: 413-6.
 42. Alenius G M, Eriksson C, Rantapaa Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?. *Clin Exp Rheumatol* 2009; 27: 120-3.
 43. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients. *Arthritis Rheum* 2008; 58: 2257-67.
 44. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 315-24.
 45. Bas S, Pernereg TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic test for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, antikeratin antibodies and IgM rheumatoid factors. *Rheumatology (Oxford)* 2002; 41: 809-14.
 46. Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. *Ann Intern Med* 2002; 137: 961-4.
 47. Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatic (PMR) and rheumatoid arthritis with PMR like onset: a prospective study. *Ann Rheum Dis* 2001; 60: 1021-4.
 48. Johnson SR, schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. *Ann Rheum Dis* 2005; 64: 770-2.
 49. Inanc N, Dalkic E, Kamah S, Kasapoglugunal E, Elbir Y, Direskeneli H, Inanc M. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. *Clin Rheumatol* 2007; 26: 17-23.
 50. Morgan C, Lunt M, Bunn D, Scott DGI, Symmons DPM. Five-year outcome of primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. *Rheumatology* 2007; 46: 1819-23.
 51. Bogliolo L, Alpini C, Caporali R, Sciré CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis *J Rheumatol* 2005; 32: 511-5.
 52. Nell VPK, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. *Ann Rheum Dis* 2005; 64: 1731-6.
 53. Schellekens GA, Visser H, de Jong BA, van der Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 2000; 43: 155-63.
 54. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. *Arthritis Rheum* 2002; 46: 357-65.
 55. El Miedany Y, Youssef S, Mehanna AN, El

- Gaafary M. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. *Joint Bone Spine* 2008; 75: 155-62.
56. Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes REM, et al. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. *Ann Rheum Dis* 2008; 67: 1194-5.
 57. Boire G, Cosette P, Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. *Arthritis Res Ther* 2005; 7: R592-603.
 58. Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. *Arthritis Rheum* 2008; 58: 359-69.
 59. Van der Helm-van Mil A, le Cessie S, van Dongen H, Breedveld FC, Toes REM, Huizinga TWJ. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. *Arthritis Rheum* 2007; 56: 433-40.
 60. Ursum J, Nielen MMJ, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BAC, et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. *Arthritis Res Ther* 2008; 10: R12.
 61. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. *Ann Rheum Dis* 2008; 67: 801-7.
 62. Kakumanu P, Sobel ES, Narain S, Li Y, Akaogi J, Yamasaki Y, Segal MS, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. *J Rheumatol* 2009; 36: 2682-90.
 63. Qing YF, Zhang QB, Zhou JG, Yuan GH, Wei J, Xing Y, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. *Lupus* 2009; 18: 713-7.
 64. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, et al. Anti-cyclic citrullinated antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. *Arthritis Res Ther* 2008; 10: R51.
 65. Ingegnoli F, Galbiati V, Zeni S, Meani L, Zalkova L, Lubatti C, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. *Clin Rheumatol* 2007; 26: 510-4.
 66. Cavagna L, Fusetti C, Montecucco CM, Caporali R. Anticyclic citrullinated antibodies as marker of erosive arthritis in antisynthetase syndrome. *J Rheumatol* 2010; 37: 9.
 67. Helliwell PS, Porter G, Taylor WJ, CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. *Ann Rheum Dis* 2007; 66: 113-7.
 68. Vander Cruyssen B, Hoffman IE, Zmierzczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. *Ann Rheum Dis* 2005; 64: 1145-9.
 69. Alenius GM, Berglin E, Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. *Ann Rheum Dis* 2006; 65: 398-400.
 70. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. *Arthritis Res Ther* 2011; 13 (Suppl 1): S4.
 71. Dalbeth N, Pool B, Smith T, Callon KE, Lobo M, Taylor WJ, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. *Arthritis Res Ther* 2010; 12: R164.
 72. Skoumal M, Haberhauer G, Fink A, Steiner A, Klingler A, Varga F, et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: a marker for unknown peripheral joint involvement? *Clin Exp Rheumatol* 2008; 26: 1087-90.
 73. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005; 64 (Suppl 2): ii14-7.
 74. Sadek HA, Abdel-Nasser AM, El-Amawy TA, Hassan SZ. Rheumatic manifestations of psoriasis. *Clin Rheumatol* 2007; 26: 488-98.
 75. Williamson L, Dockerty JL, Dalbeth N, McNally E, Ostlere S, Wordsworth BP. Clinical assessment of sacroiliitis and HLA-B27 are poor predictor of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. *Rheumatology (Oxford)* 2004; 43: 85-8.
 76. Ros Exposito S, Rodriguez Moreno J, Gomez Vaquero C, Campoy Reolid E, Roig Escofet D. Prognostic factors in the evolution of psoriatic arthritis. *Med Clin (Barc)* 1997; 108: 133-5.

77. Gladman DD. Inflammatory spinal disease in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. *J Rheumatol* 2012; 39: 418-20.
78. Gladman DD, Brubacher B, Buskilia D, Langevitz P, Farewell VT. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. *Clin Invest Med* 1993; 16: 1-7.
79. Gladman DD, Shuckett R, Russel ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA): an analysis of 220 patients. *Q J Med* 1987; 62: 127-41.
80. Gladmann DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. *J Rheumatol* 1990; 17: 809-12.
81. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. *Ann Rheum Dis* 2007; 66: 370-6.
82. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. *Ann Rheum Dis* 2003; 62: 68-70.
83. Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreuschuh M, Assmann G. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. *Clin Exp Rheumatol*. 2012; 30: 45-50.
84. Brown AK, Quinn Ma, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. *Arthritis Rheum* 2006; 54: 3761-73.
85. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone oedema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. *Arthritis Rheum* 2003; 48: 1814-27.
86. Guillemin F, Gerard N, van Leeuwen M, Smedtd LM, Kvient K, van den Heuvel W, et al. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. *J Rheumatol* 2003; 30: 2585-9.
87. Gladman DD, Farewell VT, Wong KK, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient centre II. Prognostic indicators for mortality. *Arthritis Rheum* 1998; 41: 1103-10.
88. Weiner SM, Jurenz S, Uhl M, Lange-Nolde A, Warnatz K, Peter HH, et al. Ultrasonography in the assessment of peripheral joint involvement in psoriatic arthritis: a comparison with radiography, MRI and scintigraphy. *Clin Rheumatol* 2008; 27: 983-9.
89. Wiell C, Szkudlarek M, Hasselquist M, Møller JM, Vestergaard A, Nørregaard J, et al. Ultrasonography, magnetic resonance imaging, radiography, and clinical assessment of inflammatory and destructive changes in fingers and toes of patients with psoriatic arthritis. *Arthritis Res Ther* 2007; 9: R119.
90. D'Auria MC, Scarpa R, Parodi M, Silvestri E, Garlaschi G, Cimmino MA. Magnetic resonance imaging of the peripheral joints in psoriatic arthritis. *Reumatismo* 2007; 59: 6-14.
91. McQueen FM, Dalbeth N, Doyle A. MRI in psoriatic arthritis: insights into pathogenesis and treatment response. *Curr Rheumatol Rep* 2008; 10: 303-10.
92. Cimmino MA, Parodi M, Zampogna G, Paparo F, Silvestri E, Garlaschi G, et al. Magnetic resonance imaging of the hand in psoriatic arthritis. *J Rheumatol Suppl* 2009; 83: 39-41.
93. Elder JT. PSORS1: linking genetics and immunology. *J Invest Dermatol* 2006; 126: 1205-6.
94. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as psoriasis susceptibility 1 gene. *Am J Hum Genet* 2006; 78: 827-51.
95. Pedersen OB, Svendsen AJ, Ejstrup I, Skytthe A, Junker P. On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins. *Ann Rheum Dis* 2008; 67: 1417-21.
96. Chandran V, Schentag CT, Brokbenk JE. Familial aggregation of psoriatic arthritis. *Ann Rheum Dis* 2009; 68: 664-7.
97. Nograles KE, Brasington RD, Bowcock AM. New insights into pathogenesis and genetics of psoriatic arthritis. *Nat Clin Pract Rheumatol* 2009; 5: 83-91.
98. Queiro R, Alperin M, Lopez A, Sarasqueta C, Riestra JL, Ballina J. Clical expression, but not clinical outcome, may vary according to age at disease onset in psoriatic spondylitis. *Joint Bone Spine* 2008; 75: 544-7.
99. Queiro R, Gonzalez S, Lopez-Larrea C, Alperin M, Sarasqueta C, Riestra JL, et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. *Arthritis Res Ther* 2006; 8: R185.
100. Gladmann DD, Anhorn KAB, Scachter RK, Mervant U. HLA antigens in psoriatic arthritis. *J Rheumatol* 1986; 13: 586-92.
101. Korendowych E, Dixey J, Cox B, Jones S, McHugh N. The influence of the HLA-DR B1 rheumatoid arthritis shared epitope on

- the clinical characteristics and radiological outcome of psoriatic arthritis. *J Rheumatol* 2003; 30: 96-101.
102. Queiro-Silva R, Torre-Alonso JC, Tintur -Eguren T, Lopez-Lagunas I. The effect of HLA-DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis. *Scand J Rheumatol* 2004; 33: 318-22.
 103. Grcevic D, Jajic Z, Kovacic N, Lukic IK, Velagic V, Grubisic F, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. *J Rheumatol* 2010; 37: 246-56.
 104. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF- α - and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. *J Clin Invest* 2003; 111: 821-31.
 105. Chiu YG, Shao T, Feng C, Mensah KA, Thullen, Schwarz EM, et al. CD16 (FcR γ III) as a potential marker of osteoclast precursors in psoriatic arthritis. *Arthritis Res Ther* 2010; 12: R14.
 106. Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluid are characterized by CD8 and CD4 T cell clonal expansion appear antigen driven. *J Immunol* 2001; 166: 2878-86.
 107. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. *Arthritis Res Ther* 2005; 7: R569-R580.
 108. Pontifex EK, Gerlag DM, Gogarty M, Vinckennoog M, Gibbs A, Burgman I, et al. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy. *Arthritis Res Ther* 2011; 13: R7.
 109. Robinson H, Kelly S, Pitzalis C. Basic synovial biology and immunopathology in psoriatic arthritis. *J Rheumatol* 2009; 36 (Suppl 83).
 110. van Kuijk AWR, Reinders-Blankert P, Smeets TJM, Dijkmans BAC, Tak PP. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. *Ann Rheum Dis* 2006; 65: 1551-7.
 111. Scir  CA, Epis O, Codullo V, Humby F, Morbini P, Manzo A, et al. Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of minimally invasive ultrasound guided synovial biopsy procedure. *Arthritis Res Ther* 2007; 9: R101.
 112. Torre AJ, Rodriguez PA, Arribas CJ, Ballina GJ, Riestra NJ, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. *Br J Rheumatol* 1991; 30: 245-50.
 113. McHugh NJ, Balakrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis. *Rheumatology (Oxford)* 2003; 42: 778-83.
 114. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid arthritis and psoriatic arthritis. *J Rheumatol* 2001; 28: 1842-6.
 115. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis; an early synovitis clinic experience. *Rheumatology (Oxford)* 2003; 42: 1460-8.
 116. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. *Clin Exp Rheumatol* 2006; 24 (Suppl 43): S83.
 117. Gladman DD, Hing EN, Schentag CT, Cook RG. Remission in psoriatic arthritis. *J Rheumatol* 2001; 28: 1045-8.